Telomir Pharmaceuticals, Inc. announced that Telomir, alongside its partner Frontage Laboratories, presented a scientific poster at the National University Health System of Singapore (NUHS) Centre for Healthy L longevity Conference 2024 with data showing the effect of Telomir-1 on telomere length in three human cell lines: MRC-5 fetal lung fibroblasts, human umbilical endothelial cells (HUVEC), and mesenchymal stem cells (MSC). The data presented was garnered from pre-clinical studies that Telomir previously disclosed it was undertaking. Danielle R. Baker, Ph.D., of Frontage Laboratories, presented the poster, titled ?Telomir-1 Induces Telomere Extensions in Primary Human Cell Strains,?

at the conference, which took place in Singapore, on February 29th and March 1st. The data presented further demonstrated how Telomir-1 increases telomere length and its potential to successfully affect age-related inflammatory conditions. The conference was orchestrated by the NUHS Centre for Healthy Longevity, a distinguished entity devoted to extending healthy life by delaying aging, prolonging disease-free life, and maintaining high functionality.

Through rigorous research and strategic implementations, the NUHS Centre strives to unveil and promote innovative geroprotective interventions. The CHL Conference 2024 serves as a hallmark event, reflecting the NUHS Centre's steadfast commitment to fostering a collaborative environment, facilitating discourse, and propelling the field of healthy longevity forward. As part of its ongoing work on Telomir-1, the Company collaborated with InSilicoTrials, an innovator in leveraging AI and simulations to enhance drug development, to perform advanced AI modeling on Telomir-1. Early research has confirmed the mechanism of action of Telomir-1 and suggests that it may be a potent metal inhibitor, potentially leading to a reversal of aging through telomere regeneration.

The collaboration is expected to help accelerate the development of Telomir-1, improve its safety profile, and significantly reduce the research and development costs of Telomir?s drug development program.